Executive summary
China is both a major producer of peptide APIs and a regulated market for peptide medicines. The NMPA (National Medical Products Administration) regulates drugs under the Drug Administration Law. The 2026 Implementing Regulations (effective 15 May 2026) introduced significant changes: market exclusivity periods, data protection, and four accelerated approval pathways. Online prescription medicine sale is permitted with e-prescriptions.
Authorities and legal categories
NMPA: drug registration, GMP inspection, pharmacovigilance, import licensing.
Provincial medical products administrations: enforce locally.
CDE (Center for Drug Evaluation): conducts scientific review.
Key instruments:
Drug Administration Law (2019 revision).
Implementing Regulations of the Drug Administration Law (effective 15 May 2026).
Provisions for Drug Registration.
Provisions for GMP.
| Stage | Primary control | Verification source |
|---|---|---|
| Product classification | Drug Administration Law and page-stated product category | Current NMPA record |
| Scientific review | CDE review within the NMPA system | Current CDE record |
| Registration | NMPA drug registration | NMPA Drug Registration Database |
| Manufacture or import | Registration, licensing, GMP, and the applicable API/finished-product route | Current NMPA registration and licence records |
| Distribution and online sale | Authorized product distribution and platform recording requirements | Product registration, distributor record, and platform record |
- Product classification.
- NMPA review and registration.
- Licensed manufacture or import.
- Authorized distribution.
- Recorded online platform where applicable.
- Clinical development is a side lane; accelerated review changes timing, not identity or evidence.
Approved medicines
Approved peptide medicines include semaglutide/Ozempic, tirzepatide/Mounjaro, insulin analogues (including insulin icodec — approved 2025), efsubaglutide alfa (approved 2025), liraglutide, teriparatide, octreotide, leuprolide, and desmopressin.
Source: NMPA Drug Registration Database, https://www.nmpa.gov.cn
Accelerated pathways (2026)
The 2026 Implementing Regulations introduce four pathways for eligible innovative therapeutics. Their effects and the exclusivity provisions are separated below from ordinary product registration.
Market exclusivity
| Mechanism | Eligibility described | Effect | What remains required |
|---|---|---|---|
| Breakthrough Therapy Designation | Eligible innovative therapeutics | Accelerated review pathway | Evidence, NMPA review, and product registration |
| Conditional Approval | Drugs addressing unmet medical needs | Conditional approval pathway | The applicable evidence and authorization conditions |
| Priority Review | Eligible innovative therapeutics | Priority review pathway | Product identity, evidence, and final authorization |
| Special Approval | Public-health emergencies | Special approval pathway | The applicable NMPA review and authorization requirements |
| Paediatric-indication exclusivity | Paediatric indications meeting the 2026 rules | Two years | Product authorization and the rule-specific conditions |
| Orphan-drug exclusivity | Orphan drugs meeting the 2026 rules | Seven years | Product authorization and the rule-specific conditions |
| New-chemical-entity data protection | Qualifying new chemical entities | Six years of data protection | Product authorization and the rule-specific conditions |
Compounding/manufacturing
China does not have a significant outpatient compounding sector comparable to the US, EU, or Brazil. Peptide drug products are manufactured products requiring NMPA registration and GMP certification. Compounding in hospitals is governed by hospital pharmacy regulations.
Import
Commercial peptide API and finished-medicine import generally requires NMPA registration or an applicable statutory pathway.
Peptide APIs require a Drug Registration Certificate. The 2026 regulations introduced a "bundling review" requirement for peptide APIs (API and finished product reviewed together, subject to exceptions).
Personal and clinical import exceptions are fact-specific; no conclusion about a particular shipment should be inferred from this overview.
Online sale
The 2026 regulations permit online sale of prescription medicines with a valid e-prescription from a registered medical institution.
Online platforms must be NMPA-recorded and comply with drug distribution requirements.
Peptide prescription drugs (GLP-1 agonists, insulins) can be sold online through authorised platforms.
Research-use-only products
China does not have a research-use-only exemption for consumer sales. Peptide substances sold as "research reagents" to unauthorised buyers and implied for human use are subject to enforcement under the Drug Administration Law.
Enforcement examples and uncertainty
Increasing NMPA inspection rigour for peptide API manufacturers exporting to regulated markets.
No widespread domestic enforcement against consumer peptide use comparable to US or EU action, but import controls for unapproved substances exist.
Practical interpretation limits
This is general regulatory research, not legal advice. Classification can turn on composition, claims, intended use, route, supplier role, and facts not captured by a product name.
Related atlas pages: Japan, India, cross-border supply, and global framework.
Primary sources
NMPA. https://www.nmpa.gov.cn
Drug Administration Law (2019). https://www.nmpa.gov.cn (legislation section).
Implementing Regulations (effective 15 May 2026). https://www.nmpa.gov.cn